Lupin announces closure of US FDA inspection of Nagpur facility with zero observations

This inspection from the USFDA was carried out as a part of a PreApproval Inspection at its Unit-1 oral solid dosage manufacturing facility. This inspection closed with zero FDA 483 observations. 

Source link